The Thrombin Market is expected to register a CAGR of 6.5% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the Thrombin Market is segmented by product type into bovine thrombin, human thrombin, and recombinant thrombin. Applications analyzed include surgical hemostasis, wound healing, diagnostic testing, and pharmaceutical research. End-users include hospitals, ambulatory surgical centers, research laboratories, and biotechnology companies. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses. This report examines the increasing adoption of thrombin-based hemostatic agents in surgical and trauma care, the rise of recombinant thrombin as a safer alternative to animal-derived products, and the expanding role of thrombin in biomedical research and diagnostics.
Purpose of the ReportThe report Thrombin Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Thrombin Market Segmentation
Product- Bovine Thrombin
- Human Thrombin
- Recombinant Thrombin
- Powder
- Solution
- Hospitals
- Diagnostics Centers and Clinics
Strategic Insights
Thrombin Market Growth Drivers- Increasing Surgical Procedures: The global rise in surgical procedures is a significant driver for the thrombin market. According to the World Health Organization (WHO), an estimated 313 million surgeries are performed annually worldwide, and this number continues to grow due to advancements in medical technology and an aging population. Surgical procedures, particularly in cardiovascular, orthopedic, and general surgery, require effective hemostatic agents like thrombin to manage intraoperative bleeding. The American Heart Association (AHA) reports that over 1 million cardiac surgeries are performed annually in the U.S. alone. The demand for thrombin-based hemostatic solutions is rising as surgeons seek fast-acting, reliable agents to control bleeding and improve patient outcomes. The increased adoption of robotic-assisted surgeries and minimally invasive techniques has further propelled the need for thrombin due to its rapid action and efficacy in bleeding control during complex procedures.
- Rising Prevalence of Bleeding Disorders: Bleeding disorders, such as hemophilia and von Willebrand disease, significantly contribute to the increasing demand for thrombin products. According to the Centers for Disease Control and Prevention (CDC), hemophilia affects approximately 33,000 males in the U.S., with a prevalence of 1 in 5,000 male births. Globally, the World Federation of Hemophilia (WFH) estimates that over 400,000 people are living with hemophilia. Thrombin plays a crucial role in clot formation, making it a key component in treating acute bleeding episodes and surgical interventions for patients with clotting deficiencies. The growing awareness and improved diagnostics for bleeding disorders have increased the market demand for advanced thrombin formulations, including recombinant thrombin, which offers a safer alternative to traditional plasma-derived options.
- Advancements in Biotechnology: The evolution of biotechnology has led to the development of recombinant thrombin, which eliminates the risks associated with bovine- and human-derived thrombin, such as immune reactions and transmission of infections. According to Frost & Sullivan, the global recombinant protein therapeutics market, which includes recombinant thrombin, is expected to grow at a CAGR of 7.5% from 2023 to 2030. Companies are investing heavily in R&D to improve the efficacy, stability, and safety of thrombin-based products. For instance, Pfizer and Baxter International have developed recombinant thrombin formulations that demonstrate enhanced clotting capabilities while minimizing adverse reactions. The increasing adoption of recombinant thrombin is expected to drive significant growth in the hemostatic agents market.
- Shift Toward Recombinant Thrombin: The preference for recombinant thrombin over plasma-derived or bovine thrombin is a growing trend due to concerns about immunogenicity and infection risks. Studies indicate that approximately 20% of patients exposed to bovine thrombin develop antibodies that can interfere with clotting, increasing the risk of complications. As a result, pharmaceutical companies are focusing on developing recombinant alternatives, such as Recothrom, which has shown superior safety profiles. The market for recombinant thrombin is expected to expand rapidly, with analysts projecting a CAGR of 8.2% from 2023 to 2030, reflecting a shift in clinical preference toward safer biologics.
- Integration with Surgical Sealants and Hemostats: The demand for combination products that incorporate thrombin with fibrin sealants, gelatin sponges, or collagen-based hemostats is increasing. These combination therapies enhance hemostasis, reduce blood loss, and improve wound healing. According to Global Market Insights, the surgical sealants and adhesives market is projected to reach $4.5 billion by 2028, driven by innovations in thrombin-based products. Manufacturers such as Ethicon (Johnson & Johnson) and Baxter have developed advanced thrombin-infused sealants, which improve surgical efficiency and patient outcomes.
- Expansion in Trauma and Emergency Medicine: The use of thrombin in trauma care and emergency medicine is on the rise, particularly in battlefield and pre-hospital settings. The U.S. Department of Defense has invested in research to develop portable, fast-acting thrombin-based hemostatic products for military applications.
- Regulatory Advancements and Product Approvals: Regulatory agencies such as the FDA and EMA have accelerated approvals for novel thrombin formulations, boosting market growth. In recent years, the FDA has granted approvals for several recombinant thrombin products that exhibit enhanced stability and bioactivity. For instance, in 2022, Grifols received FDA approval for a new recombinant thrombin formulation with improved clotting efficacy. As regulatory frameworks evolve to support innovation, manufacturers have increased investments in clinical trials to introduce next-generation thrombin-based products.
- Growing Demand for Hemostasis in Surgical Procedures:
As the number of surgeries, including minimally invasive procedures, increases globally, the demand for thrombin-based products to control bleeding and promote clotting during operations is expected to rise. Thrombin's use in surgical settings, such as orthopedic, cardiovascular, and neurosurgical procedures, presents a significant growth opportunity. - Advancements in Personalized Medicine for Hemostasis:
The development of personalized treatments for bleeding disorders, including the use of thrombin in tailored therapies, provides an opportunity for growth. Advances in genetic profiling and precision medicine may lead to more effective, individualized thrombin-based treatments, improving patient outcomes and increasing market demand. - Emerging Markets Adoption:
As healthcare infrastructure improves in emerging economies, there is a growing opportunity for thrombin-based products to enter new markets. The increasing prevalence of chronic conditions and the need for effective wound care and surgical hemostasis presents an opportunity for global expansion and penetration into these underserved regions.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Thrombin Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Thrombin Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Thrombin Market is expected to register a CAGR of 6.5% from 2025-2031.
The major driving factors supporting the Thrombin Market growth are- Increasing Surgical Procedures, Rising Prevalence of Bleeding Disorders, and Advancements in Biotechnology
Key Future Trends in the Thrombin Market are- Shift Toward Recombinant Thrombin, Integration with Surgical Sealants and Hemostats, and Expansion in Trauma and Emergency Medicine
Key companies in the Thrombin Market are - Bayer AG, Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck and Co., Inc., Sanofi S.A, Vetoquinol, Zoetis, Inc., Hipra, Elanco, Formosa Biomedical Inc., Shoken Pharmaceutical Co., Ltd, MSD Animal Health
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Thrombin Market - By Product
1.3.2 Thrombin Market - By Dosage Form
1.3.3 Thrombin Market - By End-Use
1.3.4 Thrombin Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. THROMBIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. THROMBIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. THROMBIN MARKET - GLOBAL MARKET ANALYSIS
6.1. THROMBIN - GLOBAL MARKET OVERVIEW
6.2. THROMBIN - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. THROMBIN MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. BOVINE THROMBIN
7.3.1. Overview
7.3.2. Bovine Thrombin Market Forecast and Analysis
7.4. HUMAN THROMBIN
7.4.1. Overview
7.4.2. Human Thrombin Market Forecast and Analysis
7.5. RECOMBINANT THROMBIN
7.5.1. Overview
7.5.2. Recombinant Thrombin Market Forecast and Analysis
8. THROMBIN MARKET - REVENUE AND FORECASTS TO 2028 - DOSAGE FORM
8.1. OVERVIEW
8.2. DOSAGE FORM MARKET FORECASTS AND ANALYSIS
8.3. POWDER
8.3.1. Overview
8.3.2. Powder Market Forecast and Analysis
8.4. SOLUTION
8.4.1. Overview
8.4.2. Solution Market Forecast and Analysis
9. THROMBIN MARKET - REVENUE AND FORECASTS TO 2028 - END-USE
9.1. OVERVIEW
9.2. END-USE MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. DIAGNOSTICS CENTERS AND CLINICS
9.4.1. Overview
9.4.2. Diagnostics Centers and Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. THROMBIN MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Thrombin Market Overview
10.1.2 North America Thrombin Market Forecasts and Analysis
10.1.3 North America Thrombin Market Forecasts and Analysis - By Product
10.1.4 North America Thrombin Market Forecasts and Analysis - By Dosage Form
10.1.5 North America Thrombin Market Forecasts and Analysis - By End-Use
10.1.6 North America Thrombin Market Forecasts and Analysis - By Countries
10.1.6.1 United States Thrombin Market
10.1.6.1.1 United States Thrombin Market by Product
10.1.6.1.2 United States Thrombin Market by Dosage Form
10.1.6.1.3 United States Thrombin Market by End-Use
10.1.6.2 Canada Thrombin Market
10.1.6.2.1 Canada Thrombin Market by Product
10.1.6.2.2 Canada Thrombin Market by Dosage Form
10.1.6.2.3 Canada Thrombin Market by End-Use
10.1.6.3 Mexico Thrombin Market
10.1.6.3.1 Mexico Thrombin Market by Product
10.1.6.3.2 Mexico Thrombin Market by Dosage Form
10.1.6.3.3 Mexico Thrombin Market by End-Use
10.2. EUROPE
10.2.1 Europe Thrombin Market Overview
10.2.2 Europe Thrombin Market Forecasts and Analysis
10.2.3 Europe Thrombin Market Forecasts and Analysis - By Product
10.2.4 Europe Thrombin Market Forecasts and Analysis - By Dosage Form
10.2.5 Europe Thrombin Market Forecasts and Analysis - By End-Use
10.2.6 Europe Thrombin Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Thrombin Market
10.2.6.1.1 Germany Thrombin Market by Product
10.2.6.1.2 Germany Thrombin Market by Dosage Form
10.2.6.1.3 Germany Thrombin Market by End-Use
10.2.6.2 France Thrombin Market
10.2.6.2.1 France Thrombin Market by Product
10.2.6.2.2 France Thrombin Market by Dosage Form
10.2.6.2.3 France Thrombin Market by End-Use
10.2.6.3 Italy Thrombin Market
10.2.6.3.1 Italy Thrombin Market by Product
10.2.6.3.2 Italy Thrombin Market by Dosage Form
10.2.6.3.3 Italy Thrombin Market by End-Use
10.2.6.4 Spain Thrombin Market
10.2.6.4.1 Spain Thrombin Market by Product
10.2.6.4.2 Spain Thrombin Market by Dosage Form
10.2.6.4.3 Spain Thrombin Market by End-Use
10.2.6.5 United Kingdom Thrombin Market
10.2.6.5.1 United Kingdom Thrombin Market by Product
10.2.6.5.2 United Kingdom Thrombin Market by Dosage Form
10.2.6.5.3 United Kingdom Thrombin Market by End-Use
10.2.6.6 Rest of Europe Thrombin Market
10.2.6.6.1 Rest of Europe Thrombin Market by Product
10.2.6.6.2 Rest of Europe Thrombin Market by Dosage Form
10.2.6.6.3 Rest of Europe Thrombin Market by End-Use
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Thrombin Market Overview
10.3.2 Asia-Pacific Thrombin Market Forecasts and Analysis
10.3.3 Asia-Pacific Thrombin Market Forecasts and Analysis - By Product
10.3.4 Asia-Pacific Thrombin Market Forecasts and Analysis - By Dosage Form
10.3.5 Asia-Pacific Thrombin Market Forecasts and Analysis - By End-Use
10.3.6 Asia-Pacific Thrombin Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Thrombin Market
10.3.6.1.1 Australia Thrombin Market by Product
10.3.6.1.2 Australia Thrombin Market by Dosage Form
10.3.6.1.3 Australia Thrombin Market by End-Use
10.3.6.2 China Thrombin Market
10.3.6.2.1 China Thrombin Market by Product
10.3.6.2.2 China Thrombin Market by Dosage Form
10.3.6.2.3 China Thrombin Market by End-Use
10.3.6.3 India Thrombin Market
10.3.6.3.1 India Thrombin Market by Product
10.3.6.3.2 India Thrombin Market by Dosage Form
10.3.6.3.3 India Thrombin Market by End-Use
10.3.6.4 Japan Thrombin Market
10.3.6.4.1 Japan Thrombin Market by Product
10.3.6.4.2 Japan Thrombin Market by Dosage Form
10.3.6.4.3 Japan Thrombin Market by End-Use
10.3.6.5 South Korea Thrombin Market
10.3.6.5.1 South Korea Thrombin Market by Product
10.3.6.5.2 South Korea Thrombin Market by Dosage Form
10.3.6.5.3 South Korea Thrombin Market by End-Use
10.3.6.6 Rest of Asia-Pacific Thrombin Market
10.3.6.6.1 Rest of Asia-Pacific Thrombin Market by Product
10.3.6.6.2 Rest of Asia-Pacific Thrombin Market by Dosage Form
10.3.6.6.3 Rest of Asia-Pacific Thrombin Market by End-Use
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Thrombin Market Overview
10.4.2 Middle East and Africa Thrombin Market Forecasts and Analysis
10.4.3 Middle East and Africa Thrombin Market Forecasts and Analysis - By Product
10.4.4 Middle East and Africa Thrombin Market Forecasts and Analysis - By Dosage Form
10.4.5 Middle East and Africa Thrombin Market Forecasts and Analysis - By End-Use
10.4.6 Middle East and Africa Thrombin Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Thrombin Market
10.4.6.1.1 South Africa Thrombin Market by Product
10.4.6.1.2 South Africa Thrombin Market by Dosage Form
10.4.6.1.3 South Africa Thrombin Market by End-Use
10.4.6.2 Saudi Arabia Thrombin Market
10.4.6.2.1 Saudi Arabia Thrombin Market by Product
10.4.6.2.2 Saudi Arabia Thrombin Market by Dosage Form
10.4.6.2.3 Saudi Arabia Thrombin Market by End-Use
10.4.6.3 U.A.E Thrombin Market
10.4.6.3.1 U.A.E Thrombin Market by Product
10.4.6.3.2 U.A.E Thrombin Market by Dosage Form
10.4.6.3.3 U.A.E Thrombin Market by End-Use
10.4.6.4 Rest of Middle East and Africa Thrombin Market
10.4.6.4.1 Rest of Middle East and Africa Thrombin Market by Product
10.4.6.4.2 Rest of Middle East and Africa Thrombin Market by Dosage Form
10.4.6.4.3 Rest of Middle East and Africa Thrombin Market by End-Use
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Thrombin Market Overview
10.5.2 South and Central America Thrombin Market Forecasts and Analysis
10.5.3 South and Central America Thrombin Market Forecasts and Analysis - By Product
10.5.4 South and Central America Thrombin Market Forecasts and Analysis - By Dosage Form
10.5.5 South and Central America Thrombin Market Forecasts and Analysis - By End-Use
10.5.6 South and Central America Thrombin Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Thrombin Market
10.5.6.1.1 Brazil Thrombin Market by Product
10.5.6.1.2 Brazil Thrombin Market by Dosage Form
10.5.6.1.3 Brazil Thrombin Market by End-Use
10.5.6.2 Argentina Thrombin Market
10.5.6.2.1 Argentina Thrombin Market by Product
10.5.6.2.2 Argentina Thrombin Market by Dosage Form
10.5.6.2.3 Argentina Thrombin Market by End-Use
10.5.6.3 Rest of South and Central America Thrombin Market
10.5.6.3.1 Rest of South and Central America Thrombin Market by Product
10.5.6.3.2 Rest of South and Central America Thrombin Market by Dosage Form
10.5.6.3.3 Rest of South and Central America Thrombin Market by End-Use
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL THROMBIN MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. THROMBIN MARKET, KEY COMPANY PROFILES
13.1. PFIZER INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. JOHNSON AND JOHNSON SERVICES INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. MALLINCKRODT PHARMACEUTICALS
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. JAPAN BLOOD PRODUCTS ORGANIZATION
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MOCHIDA PHARMACEUTICAL CO., LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OCTAPHARMA
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BAYER
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. BAXTER
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. GE HEALTHCARE
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. Pfizer Inc.
2. Johnson & Johnson Services Inc.
3. Mallinckrodt Pharmaceuticals
4. Shanghai RAAS blood products co., Ltd
5. Japan Blood Products Organization
6. Mochida Pharmaceutical Co., Ltd.
7. Octapharma
8. Bayer
9. Baxter
10. GE Healthcare
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For